Condition
Porphyria Cutanea Tarda
Total Trials
6
Recruiting
0
Active
0
Completed
5
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
60%
3 of 5 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
4Total
P 2 (3)
P 3 (1)
Trial Status
Completed5
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT03118674Phase 2CompletedPrimary
Harvoni Treatment Porphyria Cutanea Tarda
NCT01573754Phase 2CompletedPrimary
Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda
NCT00599326Phase 3CompletedPrimary
Pilot Trial of Deferasirox in the Treatment of Porphyria Cutanea Tarda
NCT01284946Phase 2UnknownPrimary
Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda
NCT00213772CompletedPrimary
Risk Factors of Porphyria Cutanea Tarda (PCT)
NCT00005103CompletedPrimary
Study of the Pathogenesis of Porphyria Cutanea Tarda
Showing all 6 trials